Back to results
US 2021/0275641 A1Published application
Biased il2 muteins methods and compositions
AssigneeSynthekine, Inc.
InventorsJan Emmerich, Steve Kauder, Scott Alan McCauley, Martin Oft
Life of this patent
Estimating the term…
Abstract
The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.
Claims22
A method of treating a subject suffering from a neoplastic disease, disorder or condition, the method comprising administrating to said subject a polypeptide that is at least 95% homologous to a polypeptide of the formula:
- 1:
- (AA1)a-(AA2)b-(AA3)c-(AA4)d-(AA5)e-(AA6)f-
- (AA7)g-(AA8)h-(AA9)i-T10-Q11-L12-Q13-L14-E15-
- H16-L17-(AA18)-L19-D20-L21-(AA22)-M23-I24-L25-
- N26-G27-I28-N29-N30-Y31-K32-N33-P34-(AA35)-L36-
- T37-(AA38)-(AA39)-L40-T41-F42-K43-F44-Y45-M46-
- P47-K48-K49-A50-T51-E52-L53-K54-(AA55)-L56-Q57-
- C58-L59-E60-E61-E62-L63-K64-P65-L66-E67-E68-
- (AA69)-L70-N71-L72-A73-(AA74)-S75-K76-N77-F78-
- H79-(AA80-(AA81)-P82-R83-D84-(AA85)-(AA86)-S87-
- N88-(AA89)-N90-(AA91)-(AA92)-V93-L94-E95-L96-
- (AA97)-G98-S99-E100-T101-T102-F103-(AA104)-C105-
- E106-Y107-A108-(AA109)-E110-T111-A112-(AA113)-
- I114-V115-E116-F117-L118-N119-R120-W121-I122-
- T123-F124-(AA125)-(AA126)-S127-I128-I129-
- (AA130)-T131-L132-T133
- wherein:
- each of a, b, c, d, e, f, g, h, and i is individually selected from 0 or 1;
- AA1 is A (wild type, a=1) or deleted (a=0);
- AA2 is P (wild type, b=1) or deleted (b=0);
- AA3 is T (wild type, c=1), C, A, G, Q, E, N, D, R, K, P, or deleted (c=0);
- AA4 is S (wild type, d=1) or deleted (d=0);
- AA5 is S (wild type, e=1) or deleted (e=0);
- AA6 is S (wild type, f=1) or deleted (f=0);
- AA7 is T (wild type, g=1) or deleted (g=0);
- AA8 is K (wild type, h=1) or deleted (h=0);
- AA9 is K (wild type, i=1) or deleted (i=0);
- AA18 is L (wild type) or R, L, G, M, F, E, H, W, K, Q, S, V, I, Y, H, D or T;
- AA22 is Q (wild type) or F, E, G, A, L, M, F, W, K, S, V, I, Y, H, R, N, D, T, or F;
- AA35 is K (wildtype) or E;
- AA38 is R (wild type), W or G;
- AA39 is M (wildtype), L or V;
- AA55 is H (wildtype) or Y;
- AA69 is V (wildtype) or A;
- AA74 is Q (wild type), P, N, H, S;
- AA80 is L (wild type), F or V;
- AA81 is R (wild type), I, D or T;
- AA85 is L (wild type) or V;
- AA86 is I (wild type) or V;
- AA89 is I (wild type) or V;
- AA91 is V (wild type), R, or K;
- AA92 is I (wild type) or F;
- AA97 is K (wild type) or Q;
- AA104 is M (wild type) or A;
- AA109 is D (wildtype), C or a non-natural amino acid with an activated side chain;
- AA113 is T (wild type) or N;
- AA125 is C (wild type), A or S;
- AA126 is Q (wild type) or H, M, K, C, D, E, G, I, R, S, or T;
- and
- AA130 is S (wild type), T, G or R.
47 more elements
(canceled)
(canceled)
8-9. (canceled)
15-17. (canceled)
22-24. (canceled)
Dependencies are inferred from the claim text.